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SUMMARY  
Melatonin is a physiological hormone involved in sleep timing and is currently used 
exogenously in the treatment of primary and secondary sleep disorders with 
empirical evidence of efficacy, but very little evidence from randomised, controlled 
studies. The aim of this meta-analysis was to assess the evidence base for the 
therapeutic effects of exogenous melatonin in treating primary sleep disorders.  
An electronic literature review search of MEDLINE (1950-present) EMBASE (1980- 
present), PsycINFO (1987- present), and SCOPUS (1990- present), along with a 
hand-searching of key journals was performed in July 2013 and then again in May 
2015. This identified all studies that compared the effect of exogenous melatonin and 
placebo in patients with primary insomnia, delayed sleep phase syndrome, Non 24-
hour sleep wake syndrome in people who are blind, and REM-Behaviour Disorder. 
Meta-analyses were performed to determine the effect of magnitude in studies of 
melatonin in improving sleep.  
A total of 5030 studies were identified; of these citations, 13 were included for review 
based on the inclusion criteria of being: double or single-blind, randomised and 
controlled. Results from the meta-analyses showed the most convincing evidence for 
exogenous melatonin use was in reducing sleep onset latency in primary insomnia 
(p=0.002), delayed sleep phase syndrome (p<0.0001), and regulating the sleep-
wake patterns in blind patients compared with placebo. 
These findings highlight the potential importance of melatonin in treating certain first 
degree sleep disorders. The development of large-scale, randomised, controlled 
trials is recommended to provide further evidence for therapeutic use of melatonin in 
a variety of sleep difficulties. 
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List of Abbreviations 
ASPS: Advanced Sleep Phase Syndrome 
CI: Confidence Intervals (Fixed, 95%) 
CGI: Clinical Global Impression 
DSM-IV: Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition 
DSM-V: Diagnostic and Statistical Manual of Mental Disorders- Fourth Edition 
DSPS: Delayed Sleep Phase Syndrome 
Hrs: Hours 
ICSD-2: International Classification of Sleep Disorders- Second Edition 
ICSD-3: International Classification of Sleep Disorders- Third Edition 
ISRCTN: International Standard Randomised Controlled Trials Number 
Mins: Minutes 
MT1/MT2: Melatonin type 1/2 receptor 
NSAIDs: Non-steroidal anti-inflammatories 
PSG: Polysomnography 
RBD: Rapid Eye Movement Behaviour Disorder/REM-Behaviour Disorder 
RCT: Randomised Control Trial 
REM: Rapid Eye Movement Sleep 
SD: Standard Deviation 
Vs: Versus  
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MELATONIN USE IN SLEEP DISORDERS 
Clinically significant sleep disorders affect at least 10% of Western populations, and 
one third or more of the population suffers daily from a sleep disturbance or 
excessive daytime sleepiness. [1] Management of many of these sleep disorders 
often requires complex therapeutic regimens, involving both pharmacological and 
non-pharmacological interventions. 
When considering pharmacological management of sleep disorders, drugs which 
have a short half-life are preferable to minimise ‘hangover’ effects the following 
morning. It is strongly recommended long term drug therapy should also be avoided, 
as dependence and tolerance can develop. [2,3] Previous studies have highlighted 
the potential use of melatonin in treating primary and secondary [4] sleep disorders 
in adults [5,6,7] and others have indicated melatonin can decrease sleep onset 
latency and increase the total time asleep, thus improving sleep quality overall. [8] 
Ferracioli-Oda et al [9] verified using melatonin in adults with primary sleep disorders 
improves sleep parameters (i.e., a higher dose has a greater effect on sleep latency 
and total sleep time). 
Melatonin was first described in 1958 by dermatologist, Aaron Lerner, [10] as a 
hormone produced by the pineal gland from the essential amino acid tryptophan (N-
acetyl-5-methoxytryptamine). Exogenous melatonin has no reported tolerance, 
dependence, or ‘hangover effect’ [11], and no adverse effect on alertness or mood 
the following day [12], as well as minimal side-effects (e.g., headache, dizziness, 
nausea, drowsiness) [13,14] if administered at a low dose. [15] Melatonin has a short 
half-life of only 30-50 minutes and can induce phase shifts in the circadian timing 
system (both central and peripheral clocks) and when administered acutely, reduces 
core body temperature and lowers alertness, encouraging sleep propensity. [16] 
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BIOLOGY OF MELATONIN 
In humans, the primary physiological function of melatonin is to reinforce darkness- 
related behaviour, such as sleep propensity. [16] Inadequate sleep can not only lead 
to a reduction in daytime performance and excessive sleepiness, but chronic 
inadequate sleep may lead to immunosuppression and increased cancer-stimulatory 
cytokine production. [17] 
Endogenous melatonin synthesis is finely regulated by visual light cues received by 
the hypothalamic suprachiasmatic nucleus in the brain, the site of the major 
circadian oscillator. During daylight hours, perceived light signals inhibit melatonin 
production. Conversely, at night when no light signals are received, melatonin 
synthesis and release occur with levels peaking in the early hours of the morning.  
Melatonin is metabolised by the liver, which processes >90% of the circulating 
hormone and together with its metabolites, is excreted in the urine. There is vast 
inter-individual variability in the quantity of melatonin produced depending on pineal 
gland size. Despite this, each person will have a similar bell-shaped production 
curve, which is reproducible from day to day. [16] Melatonin production declines as 
we age [18] due to several factors. The lower peak levels of endogenous serum 
melatonin [19] may be due to decreased pineal melatonin synthesis at night [20], or 
gradual pineal gland calcification [21]. Endogenous melatonin synthesis may be 
further reduced by drugs (e.g. benzodiazepines, NSAIDs, and calcium channel 
blockers) which many elderly patients are likely to be prescribed. Beta-blockers, 
such as albuterol, have also been shown to oppose the sympathetic stimulation of 
melatonin synthesis. [22]  
In terms of the soporific effect of acutely administered melatonin, studies have 
indicated healthy volunteers receiving a single dose (0.3mg and 1.0mg orally) of 
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melatonin had significantly improved sleep efficiency [23] and there are no 
observable toxicological or side-effects in the short-term daily use of melatonin 
(10mg for 28 days). [24] Other situations where therapeutic administration of 
melatonin has been shown to be useful include volunteers who are fully blind with 
free-running circadian rhythms where the circadian timing system is desynchronised 
from the 24-hour light-dark cycle [25,26] due to a lack of perceived external time 
cues. Thus, melatonin has a potential role in treating both disorders of sleep initiation 
and maintenance as well as circadian phase disturbance. 
In summary, exogenous melatonin administration can be used to mimic the 
physiological functions of endogenous low level melatonin when administered in a 
specifically timed manner (i.e., to correct abnormalities in circadian timing), or be 
used as a soporific/other agent when given in high doses for other types of sleep 
disorders since melatonin does not appear to suppress rapid eye movement (REM) 
sleep nor does it delay the onset of REM. [27] Recent reviews in the medical 
literature have demonstrated exogenous melatonin is safe with short term use, but 
evidence of its effects on secondary sleep disorders is of low quality. [4] 
The aim of this systematic review was to summarise the current evidence-base for 
the role of exogenously administered melatonin in the treatment of primary sleep 
disorders. 
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Primary Sleep 
Disorder 
Current Recommended Treatment Role of Melatonin 
Rapid Eye Movement-
Behavioural Disorder 
(RBD) 
1. Modify sleep environment 
2. Clonazepam; use with caution in dementia and concomitant 
obstructive sleep apnoea. [28] 
Melatonin has been recommended since 2005 - associated 
with fewer side effects and may be effective in patients 
resistant to clonazepam. [28] 
Delayed Sleep Phase 
Syndrome (DSPS) 
Schedule sleep earlier and decrease late night activity. 
Phototherapy and strict sleep schedule.[29] 
Evening administration of melatonin (0.3-5mg) between 7pm 
and 8pm shifts circadian rhythms to an earlier time.[29,30] 
Advanced Sleep Phase 
Syndrome (ASPS) 
Combined phototherapy and bright light exposure in the 
evening.[31] 
Insufficient data to recommend use of melatonin for 
treatment of ASPS in adults.[31] 
Non-REM Parasomnia Clonazepam, tricyclic antidepressants and benzodiazepines.[19] No trials conducted for the use of melatonin in parasomnias 
in adults. [19] 
Blind/non-24 h Sleep 
Wake Syndrome 
Regulation of bed-times.[32] Evening administration of melatonin achieved phase 
advance in sighted individuals.[32] Timed melatonin also 
successfully entrained rhythms in blind individuals.[33,34] 
Primary Insomnia 1. Cognitive behavioural therapy, relaxation techniques and sleep  
    hygiene measures.       
2. Non-benzodiazepine agonists and MT1/MT2 receptor agonists    
    are safer for long term use than traditional benzodiazepines.[35] 
Melatonin agonist ramelteon approved in 2005.[35] 
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METHODS 
Method: Meta-analysis of published, peer-reviewed randomised controlled trials 
(RCT) on the use of exogenous melatonin to treat primary sleep disorders. 
Search Strategy: The databases used to search the literature for this review were 
MEDLINE (1950- present), EMBASE (1980- present), PsycINFO (1987- present), 
and SCOPUS (1990- present). These databases allowed for a wide range of clinical 
medical material to be covered over a broad base of global journals. [36] Each 
database was searched between 12/07/2013 and 17/08/2013 and a hand search of 
relevant journals was conducted on 09/05/2015.  Recommendations from the 
Cochrane Collaboration for a comprehensive, sensitive, and wide variety search 
were followed to ensure all the highest standard in evidence-based research were 
undertaken and all relevant articles for this review were identified for a systematic 
review. [37-39] No conflicts of interest were identified. The following search terms 
were used; ([Melatonin] OR [Melatonin*ti,ab.]) AND [(sleep disorders) OR (insomnia* 
or DSPS or ASPS or parasomnia).ti,ab] OR (sleep adj3 disorder*).ti,ab.]. The 
additional limit was “to all adult (plus 18 years)”.   
Study Selection: All titles and abstracts were assessed and full texts of the relevant 
studies were obtained if they fulfilled the required inclusion criteria (see below). 
Selected publications were assessed by two reviewers (FA & RR) separately to 
reduce selection bias using pre-defined criteria from the Jadad scale. [40] Although 
the Jadad scale for scoring does have its critics, it is a widely-used standard 
instrument for the assessment of papers to be included in a meta-analysis. Once a 
list of articles was created that each reviewer felt met the inclusion criteria they met 
to compare results and discuss which articles would be included in the final analysis.  
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Study Type: The inclusion criteria were the trials had to be RCT, single or double-
blind, cross-over or parallel. All studies that did not meet the criteria or were not 
peer-reviewed, published trails were not included in the meta-analysis.  There was 
no time limit on trial duration. The effect of melatonin was compared with placebo 
treatment in primary sleep disorders: primary insomnia, RBD, DSPS, or non-24 h 
sleep wake disorder.  Qualitative, unpublished, duplicate studies, and those, which 
were not easily translated, were excluded.   
Study Group: Adults over the age of 18 years with an established primary sleep 
disorder.  
Date of Publication: Studies published between 1990 - 2015 were eligible. 
Sample Size: There were no restrictions on sample size. 
Data Extraction and Analysis:  The author, year of publication, number of 
participants, type of study, details of melatonin regimen, and methods used were 
recorded for each of the chosen RCTs (Table 1). Data were assessed by two 
independent reviewers and relevant extracted data were tabulated (Table 1).  Data 
were analysed using the latest reviewing software available from the Cochrane 
Collaboration: Review Manager Version 5.2. [41] Where necessary, calculations 
using standard mathematical techniques were undertaken to transform data for 
analysis.  
Meta-analysis was performed using a continuous outcome measure across all the 
included evidence. The measure of effect size was the total mean difference, 
comparing the change from baseline for both melatonin and placebo in improving 
sleep onset latency. Alternative treatments, such as cognitive-behavioural therapy 
[42] were not included to keep the meta-analysis strictly between melatonin and 
placebo and remove any other non-medication variables, such as therapy. A fixed 
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95% confidence interval (CI) for the mean difference was used to determine a 
beneficial treatment effect of melatonin compared with placebo, with a significance 
level of p<0.05. The Z-test determined an overall significance of treatment effect 
versus placebo with values of p<0.05. Heterogeneity of data was assessed using 
Chi-squared test of heterogeneity and I2 test in accordance with Cochrane 
collaboration’s guidance for assessing heterogeneity in meta-analyses. Data were 
considered heterogeneous if Chi-squared test yielded P-values <0.10 and I2 >50%. 
[43] Potential publication bias among studies was assessed by the use of funnel 
plots for each sleep disorder. 
RESULTS 
A total of 5030 articles were identified in the initial database and hand search (3696 
EMBASE, 790 MEDLINE, 496 PsycINFO, 48 SCOPUS) of journals. From this, 361 
abstracts were assessed and 28 met inclusion criteria. Fifteen articles were then 
excluded for reasons described below, resulting in a final 13 which were included 
(Fig.1). The studies included in analysis comprised a total of 1,510 patients, all aged 
between 18-80 years with either primary insomnia, DSPS, blindness, or RBD. Each 
study compared the effects of oral melatonin and placebo administration on different 
sleep parameters. The dose of melatonin ranged from 0.1mg to 10mg with treatment 
duration time ranging from two to five weeks. The outcomes and data findings for 
each included study are shown in Table 1 (Supplementary Data: Table One).  
Primary Insomnia: Primary insomnia comprises of difficulty initiating and/or 
maintaining sleep lasting for a minimum of one month, resulting in significant 
impairment of normal daytime functioning. This definition is from the International 
Classification of Sleep Disorders- Second Edition (ICSD-2) [56] and Diagnostic and 
Statistical Manual of Mental Disorders- Fourth Edition (DSM-IV), [57] which is now 
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updated as “insomnia disorder” in the International Classification of Sleep Disorders- 
Third Edition (ICSD-3) [58], and carries a slightly different definition. The ICSD-2 and 
DSM-IV definition were used in this review due to the fact that the studies assessed 
were conducted before the current versions of the ICSD-3 [58] and Diagnostic and 
Statistical Manual of Mental Disorders, Fifth Edition  
(DSM-V) [59] were published, and therefore, the participants were selected based on 
those diagnostic criteria. If these studies were replicated now using the new 
diagnostic codes, findings might differ due to slightly different populations being 
tested.  The ICSD-3 differs from the ICSD-2 in that the ICSD-2 “…described primary 
insomnia subtypes such as psychophysiological insomnia, idiopathic insomnia, 
inadequate sleep hygiene, and paradoxical insomnia, as discrete diagnostic entities.” 
[58] Patients who meet the diagnostic criteria for only one subtype are very rare and 
the diagnostic criteria have been established for the subtypes of insomnia 
“…represent generic characteristics (e.g., engaging in sleep-disruptive habits; 
underestimation of sleep time, evidence of conditioned arousal) of insomnia…and do 
not facilitate discrimination among these subtypes or between these subtypes and 
those presumed to have “secondary” forms of insomnia.” [58] The ICSD-3 also 
states, “…the current manual abandons the previously employed complex and highly 
specific insomnia classification scheme described by the original ICSD and the 
ICSD-2 in favour of a more global and defensible nosology.” The ICSD-3 now 
includes three categories to diagnose insomnia: chronic insomnia disorder, short-
term insomnia disorder, and other insomnia disorder. [58]  
Primary insomnia is not due to a medical or psychiatric condition or 
medicine/substance abuse. It is particularly common in the elderly population and is 
often a long term problem; 69% of older people monitored for one year still suffer 
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from the condition due to their vulnerability to persistent symptoms and the 
decreased production of endogenous nocturnal melatonin. [60-62] Haimov et al. 
recommend melatonin replacement therapy may prove beneficial due to peak 
excretion of melatonin being almost half that of younger patients. [63] Vural et al’s 
[64] review reports melatonin is effective in older adults, but advises in order to avoid 
prolonged, supra-physiological blood levels, older adults should use the lowest dose 
possible of immediate-release melatonin as long-term effects have not been studied. 
Abhinav et al [65] reported melatonin is beneficial in older adults for metabolic 
syndrome components when used in 10-week periods and Haimov et al [66] 
reported melatonin can be safe and effective for up to two months of treatment.  
Quantitative analysis of the five eligible RCTs [44,46-49] showed an overall 
significant reduction in the time to fall asleep between the effect on sleep onset 
latency for melatonin in patients with primary insomnia compared with placebo (Total 
mean difference = -5.05 minutes, 95% CI: -8.51, -1.59). The overall estimated score 
of melatonin treatment was significant (Z=2.86, P=0.004) (Fig.2). No significant 
heterogeneity was present across the five studies (  =3.19, P=0.53, I2=0%). There 
was no asymmetry in funnel plots suggesting there was no reporting bias between 
the studies. 
In all five studies for primary insomnia [44-49] there were large sample sizes, which 
increased reliability of results (n=40-791).  The studies used a thorough pre-
screening assessment which was deployed to reduce confounding factors and use of 
medications such as benzodiazepines were stopped beforehand.  
Delayed Sleep Phase Syndrome: DSPS is the most common circadian rhythm 
disorder, causing delayed habitual bedtime and delayed rising time, roughly three to 
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six hours after conventional sleep-wake times. It is particularly common in 
adolescents and can be also associated with depression. [67,68] 
Meta-analysis of the two eligible trials [52,53] investigating the role of melatonin in 
treating DSPS demonstrated an overall significant improvement in sleep onset 
latency compared with placebo (total mean difference = -22.05 minutes, 95% CI: -
32.02, -12.09). The overall estimated score of melatonin treatment was significant 
(Z=4.34, P<0.0001) (Fig.3). There was significant heterogeneity between these two 
studies (  =7.76, P=0.005, I2=87%). There was slight asymmetry in the funnel plot, 
indicating there was potential publicaiton bias present. 
The two studies diverged in the way sleep was measured (e.g., PSG versus wrist 
actigraphy), and by method of melatonin administration (e.g., 5mg daily for four 
weeks versus 5mg for two weeks double-blind and two weeks open setting, 
successively or interrupted with two weeks of placebo). Nevertheless, both studies 
highlighted a decrease in sleep onset latency after melatonin administration.  
The third study included for DSPS in this review [51] showed melatonin significantly 
reduced REM latency and wake time. However, there was no effect on total sleep 
time or alertness ratings. This indicates a potential role for melatonin in inducing 
phase-shift in sleep times for patients with DSPS. 
One study used adolescents and young adults (aged 16-25) [69,70] examining the 
measures of subjective and objective sleepiness and cognitive function focusing on 
the short- and long-term effects of bright light and melatonin coupled with advanced 
rise times. Gradual advanced rise times coupled with bright light and melatonin were 
found to be effective with patients with DSPS immediately as well as showing lasting 
effectiveness over time. We recognize the combination of bright light and melatonin 
created a positive effect on sleep, which might make it difficult to tease out an 
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independent effect of melatonin; it would be beneficial to replicate this study in older 
adults to compare it to other studies reviewed.   
Non 24-hour Sleep Wake Syndrome in Blind Patients: Non 24-hour sleep wake 
syndrome is almost exclusively seen in people who are completely blind or have 
visual impairment with an absence of light perception. It rarely affects the general 
population and it is largely associated with behavioural issues and psychiatric illness. 
This syndrome involves progressive delay of sleep onset time due to a lack of light 
perception by the photoreceptor cells located in the retina resulting in a cyclic non-24 
h sleep wake disorder characterised by periods of short night sleep and severe 
daytime sleepiness. 
Three studies [54,55,58] highlighted the use of melatonin in phase advancement and 
entrainment of circadian rhythm in patients who are blind. Two of these trials [54,55] 
were eligible for meta-analysis. There was no overall significant difference between 
the effects of melatonin and placebo on sleep onset latency in blind patients (total 
mean difference = -3.17 minutes, 95% CI: -11.88-5.54). It is speculated that the use 
of melatonin has no effect when used on nights when the circadian rhythm is 
congruent with pre-established/routine sleep habits, reinforcing the concept that 
melatonin does not provoke sleep but facilitates the desire to sleep when awake. [55] 
The overall estimated score of treatment effect for these patients was not significant 
(Z=0.71, P=0.48). No significant heterogeneity was found between these compared 
studies (  =0.00, P=0.99, I2=0%). No publication bias was present indicated by the 
symmetrical funnel plot (Fig.4). 
Only subjective measures were used by Hack et al [54] to assess sleep parameters 
with a small sample size (n=10). The use of daily diary reporting measures increased 
the likelihood of bias due to inaccurate reporting and therefore PSG or wrist 
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actigraphy methods would have been more reliable, more representative of sleep 
behaviour, and a less erroneous strategy. In comparison, Sack et al [55] used PSG 
which increased reliability of the findings despite the similarly small sample size 
(n=7). A reduction in total sleep time after melatonin administration was also shown, 
due to melatonin inducing additional consolidated sleep in blind patients and 
shortening their overall sleep time by reducing frequency of daytime napping. Thus, 
melatonin is an effective treatment to promote the free-running circadian rhythm in 
these patients, allowing for a more structured 24-hour sleep-wake cycle. 
REM-Behaviour Disorder: RBD involves loss of normal voluntary muscle, atonia, 
during REM sleep resulting in complex motor behaviour (the body is active instead of 
being paralysed) when dreaming. RBD is predominantly seen in males and is more 
common in the elderly. [71] 
Only one study has addressed the role of melatonin in the treatment of this disorder. 
[50] Participants were administered 3mg of melatonin daily over 4 weeks. A small 
sample size was used (n=8, all male), but results highlighted a significant 
improvement in clinical global impression (CGI) (6.1 vs 4.6; P=0.024) and 
improvement in REM sleep muscle atonia (39% vs 27%; P=0.012), despite the 
heterogeneity of the RBD included. This provided evidence in favour of melatonin as 
a useful adjunct to clonazepam which is often prescribed in the treatment of RBD. 
There were sufficient pre-screening measures taken before participation in the trial, 
such as alcohol avoidance and prohibiting exercise, since studies have shown 
exercise can improve symptoms of RBD. [72] The authors concluded any 
improvement in sleep parameters was due to melatonin administration alone in this 
trial. 
Discussion 
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This review has shown evidence that melatonin has a role in the treatment of some 
primary sleep disorders, namely primary insomnia, DSPS, non-24 hour sleep-wake 
disorder in people who are blind, and RBD. Melatonin facilitates achieving better 
sleep for these patients by reducing the sleep-onset latency [73] or by regulating 
sleep-wake times to coincide with the natural circulatory cycle, as well as reducing 
sleep episodes without muscle atonia. [50] The mechanism by which the occurrence 
of reducing sleep episodes without muscle atonia in RBD is still unknown and 
requires further study. 
The search strategy used in this review was thorough and the inclusion criteria were 
broad so all relevant publications from a wide variety of sources from 1950 to 2014 
were included. There is unpublished research and commercially sponsored work in 
the area of sleep disorders, but the data were not included in this review due to the 
fact that unpublished research has not been subject to peer review. Futhermore, 
commercially sponsored/sensitive work can potentially be biased and/or contain 
inaccurate data. Kuriyama et al [74] reviewed published and unpublished data from 
randomised placebo-controlled trials performing an analysis on the efficacy of 
ramelteon, a selective melatonin receptor agonist used in the treatment of insomnia. 
Ramelteon was effective in improving some sleep parameters with insomnia, was 
not included in the meta-analysis as we focused on exogenous melatonin only. After 
we had concluded our analysis, Lockley et al [75] published the effectiveness of 
once-daily tasimelteon, which is a new dual-melatonin receptor agonist in non-24 h 
sleep/wake disorder in blind people. Tasimelteon was found to be effective in 
entraining totally blind people, but continued treatment was necessary to maintain 
the improvements. Again, our focus was on melatonin per se. Brzezinski et al [98] 
conducted a similar meta-analysis of randomised, placebo-controlled trials of 
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
17 
 
melatonin in healthy normal volunteers, individuals with insomnia, Alzheimer’s 
disease patients, and individuals with schizophrenia. Although our analysis focused 
on individuals with established primary sleep disorders, Brzezinski’s findings that 
melatonin decreased sleep onset latency, reinforce our conclusions. Brzezinski also 
reported similar findings to the publications we reviewed noting melatonin increased 
sleep efficiency and total sleep duration. [76] 
The most relevant databases for this topic were chosen; MEDLINE, EMBASE, and 
SCOPUS cover a wide range of medical topics from across Europe and 
internationally and provide studies performed recently. PsycINFO is a comparatively 
smaller database, but indexes more than journal articles alone; it is also useful for 
social aspects of medicine. [35] Papers which were included for analysis were 
reviewed by two authors independently using defined inclusion criteria and then 
discussed to ensure they were relevant and appropriate. All studies used a variety of 
sleep measures to assess the effect of melatonin on sleep which provides a broad 
set of variables, thus impacting on the reliability of results. The symmetrical funnel 
plots for primary insomnia and blindness demonstrated the negligible publication 
bias present in this meta-analysis. This use of funnel plots was important as it 
quantified and evaluated publication bias rather than it being discussed in a 
superficial and abbreviated manner. Publication bias cannot be excluded through the 
use of a funnel plot alone, since “…asymmetry should be used when there are at 
least 10 studies included in the meta-analysis, because when there are fewer studies 
the power of the tests is too low to distinguish chance from real asymmetry.” [77] 
However, we used this tool to alert us to any problems which needed to be 
considered in the meta-analysis.  
M
AN
US
CR
IP
T
 
AC
CE
PT
ED
ACCEPTED MANUSCRIPT
 
 
18 
 
There were some potential limitations to the review; only published study data were 
included which may increase susceptibility to publication bias. It was particularly 
evident in the funnel plot for studies investigating DSPS (Fig.3), whereby all trials 
were distributed around the line of no effect; it is unlikely that studies with negative or 
findings of no effect would be ultimately published. Unfortunately, this is a common 
theme in scientific and medical publications. Funnel plots give an idea of whether the 
study results are scattered symmetrically around a central effect of melatonin on 
primary sleep disorders, however asymmetry may also be due to heterogeneity 
between the studies. [78] We focused on primary sleep disorders as previous meta-
analyses have been conducted on secondary sleep disorders and shift-work 
diagnosis specifically. [79]  
Some RCTs included in our meta-analysis had only a small number of participants 
(Table 1), which may not be representative of the large population afflicted by these 
sleep disorders. [80] Furthermore, not all studies included in the search were eligible 
for meta-analysis, as they differed with respect to sleep outcomes measured (i.e., 
some studies assessed the role of melatonin on sleep parameters other than sleep 
onset latency). Nevertheless, the findings from the trials included were still 
convincing and highlight the potential for further large-scale studies in the future.  
This review has focused on the effects of melatonin on adult patients with much of 
the insomnia work carried out in those aged 55-80 years, as sleep disorders have 
increased prevalence in this age group. Studies have shown melatonin can lack 
effectiveness depending on the circumstances relating to when it is taken, dose, if it 
a quick or slow release formula, and on some clinical disorders. [81] Further 
investigation needs to be done to assess its effectiveness at varying times, varying 
dose, and comparing variable ways of dose intake. However, further research may 
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be hindered by the intellectual property issues around the use of melatonin and lack 
of financial incentives that  may decrease the motivation to undertake such trials. 
Funding agencies are more likely to support research on novel medications, which 
leads to new treatments and increased revenue for pharmaceutical companies, than 
to supply funding for a supplement (melatonin) that has been easily purchased over 
the counter since the 1990’s in some countries. Since studies are continuously being 
developed and deployed a search of the International Standard Randomised 
Controlled Trials Number (ISRCTN) [82] registry yielded few current studies focusing 
on the benefits of melatonin on participants who have sepsis or cancer and on 
asphyctic newborns, but none focusing on primary sleep disorders assessed in this 
review. 
Numerous studies have also highlighted the use of melatonin in paediatric sleep-
wake cycle disorders and AD’s, [83] however there have been no RCTs or long term 
studies showing evidence for its therapeutic use in this age group.   
Little evidence is available regarding the potential adverse effects of long-term 
melatonin use as it may take years for the toxicities to develop. [84] Wade et al [48] 
preformed a trial over six months of daily melatonin use and demonstrated no 
adverse effects or rebound withdrawal symptoms. Two studies [62, 85] investigated 
the treatment of primary insomnia of older people (aged ≥55) with melatonin (2mg 1-
2 hours before bedtime orally) and concluded long-term use of melatonin (for 13-24 
weeks) is well-tolerated, safe, and effective. Zhang et al. also reported that 
exogenous melatonin improves sleep quality in elderly individuals with underlying 
neurodegenerative disorders. [86] However, there have been concerns regarding 
chronic use of melatonin; in large doses it can interact with other medications and 
also suppress reproductive hormones over long periods of time. [87] Side-effects 
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potentially include headaches, dizziness, vomiting, and nausea. [78] Since melatonin 
physiology varies between individuals, it is important to consider the optimum dose 
required when prescribing the hormone exogenously. Buscemi et al. reported that 
melatonin is not effective in treating secondary sleep disorders or sleep disorders 
that arise from sleep restriction (e.g., jet lag, shift-work), [4] but the results of their 
review may be partly attributable to trial limitations similar to those discussed in the 
current paper.  
In conclusion, this review has found evidence from a small number of trials for 
melatonin in treating primary insomnia, DSPS, and Non 24-hour sleep wake 
syndrome in people who are blind. Meta-analyses of the data emphasised in 
particular the improvement of sleep onset latency with melatonin in these patients. 
This result has been reproduced in the meta-analysis by Ferracioli-Oda, et al. [9] 
Based on the current inclusion of melatonin in the management of RBD, it is hoped 
in future there will be an increase in robust evidence for its widespread use. For such 
a commonly used medication, there are very few trials which have been performed 
sufficiently rigorously to examine the long-term efficacy of exogenous melatonin or 
any long-term side-effects. Clinicians should be alert to these limitations but also 
aware of the important role exogenously administered melatonin has in the sleep 
medicine armamentarium.  
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Practice Points 
1. Exogenously administered melatonin has been shown to improve sleep onset 
latency in primary insomnia, DSPS, and to normalise free-running rhythms in 
people who are blind. 
2. Melatonin may play a role in the treatment of RBD. 
3. There is currently no evidence of efficacy of melatonin for treating arousal 
disorders in adults. 
4. There is currently no trial evidence for the use of melatonin in secondary 
insomnia; since this is no longer a diagnosable DSM-V disorder there will 
probably not be any future studies on secondary insomnia [88].   
 
Research Agenda 
1. There is an absolute lack of well-structured clinical trials focusing on the utility 
and efficacy of melatonin in the treatment of RBD, arousal disorders and adult 
secondary insomnia. 
2. The efficacy of different formulations of melatonin and timing of administration in 
the treatment of various sleep disorders needs to be ascertained in RCTs.
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Fig.2: Effect of Melatonin on Sleep Latency in Primary Insomnia:  
(A) Conventional meta -analysis with fixed 95% confidence intervals using Cochrane 
RevMan Software. Squares indicate mean difference between melatonin and placebo on 
sleep onset latency in patients with primary insomnia. Horizontal lines indicate 95% 
confidence intervals for the mean difference in effect. Diamond represents pooled mean 
effect with 95% confidence intervals in favour of melatonin improving sleep onset latency. All 
mean and standard deviation (SD) values in minutes. (B) Symmetrical funnel plot indicated 
minimal publication bias. SE(MD): Standard error of the mean difference  
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Fig.3: Effect of Melatonin on Sleep Latency in DSPS 
(A) Conventional meta -analysis with fixed 95% confidence intervals using Cochrane 
RevMan Software. Squares indicate mean difference between melatonin and placebo on 
sleep onset latency in patients with DSPS. Horizontal lines indicate 95% confidence intervals 
for the mean difference in effect. Diamond represents pooled mean effect with 95% 
confidence intervals in favour of melatonin improving sleep onset latency. All mean and SD 
values in minutes. (B) Slight asymmetry of funnel plot indicated potential for publication bias. 
SE(MD): Standard error of the mean difference  
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Fig.4: Effect of Melatonin on Sleep Latency in Blind Patients 
(A) Conventional meta -analysis with fixed 95% confidence intervals using Cochrane 
RevMan Software. Squares indicate mean difference between melatonin and placebo on 
sleep onset latency in patients with sleep wake disorder in association with blindness. 
Horizontal lines indicate 95% confidence intervals for the mean difference in effect. Diamond 
represents pooled mean effect with 95% confidence intervals in favour of melatonin 
improving sleep onset latency. All mean and SD values in minutes. (B) Symmetrical funnel 
plot indicated minimal publication bias. SE(MD): Standard error of the mean difference  
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